1-20 of 155
Daniel J. Deangelo, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Giovanni Martinelli, MD, Elisabetta Todisco, MDPhD, Andrew A Lane, MD PhD, Evelyn Acuña-Cruz, MD, Eric Deconinck, MDPhD, Eunice S. Wang, MD, Kendra L. Sweet, MD MS, David A Rizzieri, MD, Luca Mazzarella, MDPhD, Daniel J. DeAngelo, MD PhD, Pau Montesinos, MD PhD, Corrado Tarella, Harry P. Erba, MD PhD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Callum M Sloss, PhD, Kara E Malcolm, RN, Patrick A Zweidler-McKay, MDPhD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-139903
Published: 2020
Journal Articles

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Jacqueline S. Garcia, MD, Yael Flamand, MS, Benjamin K. Tomlinson, MD, Michael Keng, MD, Lourdes M. Mendez, MD PhD, Samer Khaled, MD, Asad Bashey, MD PhD, Andrew M. Brunner, MD, Alexandra Savell, BS, Donna Neuberg, Ilene Galinsky, Marlise R. Luskin, MD, David P. Steensma, MD, Martha Wadleigh, MD, Eric S. Winer, MD, David E. Avigan, MD, Nicole Cullen, Scott Rodig, MD PhD, Livius Penter, R. Coleman Lindsley, MD PhD, Stephanie Andrews, Matthew S. Davids, MD, Catherine J. Wu, MD, Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Robert J. Soiffer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-136235
Published: 2020
Journal Articles

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Jacqueline S. Garcia, MD, Haesook Kim, Corey Cutler, MD MPH, FRCPC, Eric S. Winer, MD, Richard M. Stone, MD, Vincent T. Ho, MD, Rizwan Romee, MD, John Koreth, MBBS, DPhil, Mahasweta Gooptu, MD, Sarah Nikiforow, MD PhD, Roman M Shapiro, MD, David P. Steensma, MD, Marlise R. Luskin, MD, Martha Wadleigh, MD, Fiona Loschi, Jeremy Ryan, Anthony Letai, R. Coleman Lindsley, MD PhD, Jennifer Brock, Robert J. Soiffer, MD, Daniel J. DeAngelo, MD PhD, Joseph H. Antin, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134947
Published: 2020
Journal Articles

Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study

Jason Gotlib, MD MS, Deepti H. Radia, MRCPI, FRCPath, Tracy I. George, MD, William A Robinson, MD PhD, Albert T. Quiery, MD, Mark W. Drummond, PhD FRCPath, Prithviraj Bose, MD, Elizabeth O. Hexner, MD, Elliott F. Winton, MD, Hans-Peter Horny, Prof, Dr, Meera Tugnait, PhD, Oleg Schmidt-Kittler, PhD, Erica K. Evans, PhD, Hui-Min Lin, PhD, Brenton G. Mar, MD PhD, Michael W. Deininger, MD PhD, Daniel J. DeAngelo, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-137413
Published: 2020
Journal Articles

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Cem Akin, MDPhD, Hanneke Oude Elberink, MD PhD, Jason Gotlib, MD MS, Vito Sabato, MD PhD, Karin Hartmann, MD, Sigurd Broesby-Olsen, MD, Mariana Castells, MD PhD, Tsewang Tashi, MD, Mark L Heaney, MD, Tracy I. George, MD, Frank Siebenhaar, MD, Deepti H. Radia, MRCPI, FRCPath, Massimo Triggiani, MD PhD, Paul van Daele, MD, Daniel J. DeAngelo, MD PhD, Iván Alvarez-Twose, MD PhD, Andreas Reiter, MD, Peter Vadas, MD PhD, Patrizia Bonadonna, MD, Paggy Hew, MS, Hui-Min Lin, PhD, Maria Roche, MS, Marcus Maurer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-136632
Published: 2020
Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Hagop M. Kantarjian, MD, Michael W. Deininger, MD PhD, Elisabetta Abruzzese, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Charles Chuah, MD, Daniel J. DeAngelo, MD PhD, John F. DiPersio, MD PhD, Andreas Hochhaus, MD, Jeffrey H. Lipton, MD PhD, Franck E Nicolini, MDPhD, Javier Pinilla Ibarz, MD PhD, Delphine Rea, MDPhD, Gianantonio Rosti, MD, Philippe Rousselot, MDPhD, Neil P Shah, MD PhD, Moshe Talpaz, MD, Shouryadeep Srivastava, MBBS, PhD, Vickie Lu, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-133922
Published: 2020
Journal Articles

Orthopedic Toxicity Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials

Yannis K. Valtis, MD, Kristen E. Stevenson, MS, Andrew E. Place, MDPhD, Lewis B. Silverman, MD, Lynda M. Vrooman, MD, Giacomo Gotti, MD, Andrew M. Brunner, MD, Mary Nauffel, Daniel J. DeAngelo, MD PhD, Marlise R Luskin, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-137488
Published: 2020
Journal Articles

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2 -Mutant Myeloproliferative Neoplasms

Debra Van Egeren, Javier Escabi, *, Maximilian Nguyen, *, Shichen Liu, Christopher R. Reilly, MD, Sachin Patel, Baransel Kamaz, MD, Maria Kalyva, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Martha Wadleigh, MD, Eric S. Winer, MD, Marlise R Luskin, MDMS, Richard M. Stone, MD, Jacqueline S. Garcia, MD, Gabriela S. Hobbs, MD, Fernando D Camargo, PhD, Franziska Michor, PhD #, Ann Mullally, MD, Isidro Cortes-Ciriano, PhD #, Sahand Hormoz, PhD #
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-141643
Published: 2020
Journal Articles

Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Anthony G. Letai, MD PhD, Jeremy M. Stewart, BA, Michael McGinnis, Francis Brown, JD, Geoffrey Fell, Yael Flammand, Marina Konopleva, MD PhD, Jacqueline S. Garcia, MD, Marlise R Luskin, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-140646
Published: 2020
Journal Articles

Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Gail J. Roboz, MD, Daniel J. DeAngelo, MD PhD, David A. Sallman, MD, Monica L. Guzman, PhD, Pinkal Desai, MDMPH, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Francisco Javier Esteva, MD PhD, Andrew Garton, Kate Backhouse, Roman Galetto, PhD, Carrie Brownstein, MD, Naveen Pemmaraju, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-138984
Published: 2020
Journal Articles

A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval Daver, MD, Kendra L. Sweet, MD MS, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Ahmed Aribi, MD, Daniel J. DeAngelo, MD PhD, Harry P Erba, MDPhD, Giovanni Martinelli, MD, Roland P Walter, MDPhD, Jessica K Altman, MD, Anjali S Advani, MD, Antonio Curti, MDPhD, Callum M Sloss, PhD, Kara E Malcolm, RN, Patrick A Zweidler-McKay, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-139884
Published: 2020
Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker
Journal: Blood
Blood (2019) 134 (Supplement_1): 665.
https://doi.org/10.1182/blood-2019-124716
Published: 2019
Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Jacqueline S Garcia, MD, Haesook T. Kim, PhD, Jennifer Brock, Amy Han, MPH, Jeremy A. Ryan, SM, Thelma Mashaka, BA, Anthony G. Letai, MD PhD, R. Coleman Lindsley, MD PhD, Mahasweta Gooptu, MD, Vincent T. Ho, MD, John Koreth, MBBS, DPhil, Sarah Nikiforow, MD PhD, Rizwan Romee, MD PhD, Ilene Galinsky, Martha Wadleigh, MD, David P. Steensma, MD, Richard M. Stone, MD, Robert J. Soiffer, MD, Corey Cutler, MD MPH, FRCPC, Daniel J. DeAngelo, MD, Joseph H. Antin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 258.
https://doi.org/10.1182/blood-2019-126172
Published: 2019
Journal Articles

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Caron A. Jacobson, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Daniel J. DeAngelo, MD, Christopher Heery, MD, Anthony Stein, MD, Michael D. Jain, MD PhD, Bijal Shah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4107.
https://doi.org/10.1182/blood-2019-128203
Published: 2019
Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Cem Akin, MD PhD, Vito Sabato, Jason Gotlib, MD MS, Mariana Castells, Michael W. Deininger, Hanneke Oude Elberink, Mark L Heaney, Paul van Daele, Deepti Radia, Massimo Triggiani, Daniel J. DeAngelo, MD, Iván Alvarez-Twose, Sigurd Broesby-Olsen, Tracy I. George, MD, Karin Hartmann, Siebenhaar Frank, Andreas Reiter, Peter Vadas, Patrizia Bonadonna, Jens P. Panse, Petra Staubach-Renz, Knut Brockow, Diamant Thaci, Hui-Min Lin, Andrew Morrison, Brenton Mar, Marcus Maurer
Journal: Blood
Blood (2019) 134 (Supplement_1): 2950.
https://doi.org/10.1182/blood-2019-126035
Published: 2019
Journal Articles

Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL

Amy Guillaumet-Adkins, PhD, Praveen Anand, PhD, Huiyoung Yun, PhD, Yotam Drier, PhD, Anna Rogers, Madhu M. Ouseph, Monica S. Nair, Sayalee Potdar, Randi Isenhart, Jake A. Kloeber, Tushara Vijaykumar, Guangwu Guo, Julia Frede, PhD MPhil, Marian H. Harris, MD PhD, Lewis B. Silverman, MD, Andrew A. Lane, MD PhD, Daniel J. DeAngelo, MD, Jon C. Aster, MD PhD, Bradley E. Bernstein, MD PhD, Jens G. Lohr, MD PhD, Birgit Knoechel, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3953.
https://doi.org/10.1182/blood-2019-130482
Published: 2019
Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3908.
https://doi.org/10.1182/blood-2019-124966
Published: 2019
Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

Marlise Luskin, MDMS, Mark A. Murakami, MDMA,MMSc, Kristen E. Stevenson, MS, Martha Wadleigh, MD, Malgorzata McMasters, MD, Peter Winter, PhD, David M. Weinstock, MD, Richard Stone, MD, Daniel J. DeAngelo, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3879.
https://doi.org/10.1182/blood-2019-125138
Published: 2019
Journal Articles

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Nitin Jain, MD, Kristen E. Stevenson, MS, Eric S. Winer, MD, Jacqueline S Garcia, MD, Richard M. Stone, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Jeremy M. Stewart, BA, Dean R Legg, BA, Hagop M. Kantarjian, MD, Donna S Neuberg, ScD, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Daniel J. DeAngelo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3867.
https://doi.org/10.1182/blood-2019-129988
Published: 2019
Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2690.
https://doi.org/10.1182/blood-2019-123744
Published: 2019